The Regulator

CMS finalizes its organ procurement rule: an organ procurement organization whose service areas all fall in the bottom tier will be decertified. The Centers for Medicare & Medicaid Services (CMS) final rule, CMS-3409-F, revises the Conditions for Coverage for organ procurement organizations (OPOs), the nonprofit groups that secure donor authorization and recover organs for transplant. The two performance measures, donation rate and transplantation rate, and the three-tier structure are unchanged. Tier 1 areas qualify for four-year recertification, tier 2 areas must compete to keep their territory, and an OPO with only tier 3 areas is decertified and cannot compete for other open areas. The rule also defines “unsound medical practices” as failures that create an imminent threat to patient health and safety, giving CMS a basis for immediate decertification, and it requires incumbents to cooperate with successor OPOs, which must file transition plans. Who it hits: every OPO, plus the transplant centers and hospitals that depend on them. So what: more than 100,000 Americans are waiting for a transplant, and CMS says donations are up 36% and transplants up 30% since the 2020 rule. CMS’s release and fact sheet give no effective date, no assessment dates and no count of affected OPOs, and CMS lists the rule as Federal Register document 2026-22381, which we could not retrieve from the Federal Register, so check the rule text for timing. Confidence: High on the provisions, from CMS’s own fact sheet; Low on timing. Sources: CMS final rule fact sheet, CMS press release.

ACA open enrollment for 2027 opens Sunday, November 1, and CMS says more than 75% of HealthCare.gov buyers will find premiums of $50 or less. CMS’s Plan Year 2027 plans-and-prices fact sheet says enrollment runs November 1, 2026 through January 15, 2027. It reports about 100 plans on average, offered by five to six insurers, and about 35 plans eligible for health savings accounts (HSAs) on average. It also says the lowest-cost catastrophic plan averages nearly 10% cheaper than the next-lowest-cost plan at other coverage levels. Who it hits: marketplace shoppers and brokers. So what: the fact sheet gives no average premium, benchmark premium change or issuer count, and does not say whether the $50 figure is monthly or after subsidies, so do not read it as a price drop. Early filings pointed the other way: KFF found a median proposed increase of 14% in 16 states and the District of Columbia. Confidence: High on the CMS figures; Med on the premium picture, which rests on preliminary filings. Sources: CMS Plan Year 2027 fact sheet. Supplemental: KFF analysis of preliminary 2027 rate filings.

FDA grants accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy in the United States, for recurrent respiratory papillomatosis. The Food and Drug Administration (FDA) announcement, dated October 30, covers adults with the disease, a rare condition caused by human papillomavirus (HPV) types 6 and 11 that grows wart-like tumors in the airways, most often the larynx. Inovio Pharmaceuticals’ product is injected into muscle with an electroporation device. In an open-label trial of 32 adults, 7 of 26 patients (27%) who had at least three surgeries before treatment needed no surgery in the following year. Who it hits: patients facing repeated airway surgery, and the surgeons and payers who cover them. So what: approval rests on fewer surgeries, an intermediate endpoint, so the manufacturer must run confirmatory trials, and FDA’s announcement gives no price. Confidence: High. Source: FDA press announcement.

DEA places the new ADHD drug centanafadine in Schedule III, effective immediately, with comments due November 30. The Drug Enforcement Administration (DEA) interim final rule, published October 30, covers centanafadine and its salts and isomers. FDA approved the drug, sold as Simtriyo, for adult and pediatric attention-deficit/hyperactivity disorder (ADHD) on July 24, 2026. Who it hits: prescribers, pharmacies and distributors, who must handle it under federal controlled-substance rules from the first day. So what: scheduling by interim final rule means the controls apply now while comments stay open until November 30. Confidence: High. Source: Federal Register interim final rule.

UPDATE: Missouri gets $39.7 million for 26 rural providers, and West Virginia gets more than $19 million, from the $50 billion Rural Health Transformation Program. We covered the Texas and California awards October 30. CMS’s October 30 Missouri release says the money lets providers renovate and equip facilities for labor and delivery rooms, behavioral health for older adults and people with substance use disorders, and diagnostic equipment including MRI, mammography and ultrasound. CMS says the program runs for the remaining four years, and its West Virginia release cites telehealth, specialty care and the health workforce. Who it hits: rural clinics and hospitals in both states. So what: awards go to named providers, not whole communities, so check recipient lists before assuming a local hospital is funded. Confidence: High on amounts; the West Virginia detail comes from CMS’s release headline only. Sources: CMS release on Missouri, CMS release on West Virginia.

FDA delays to May 4, 2027 the effective date of its action on estrogen-androgen combination drugs. The Federal Register notice, published October 30, extends for the third time the effective date of FDA’s May 27, 2026 final resolution for Drug Efficacy Study Implementation 7661, moving it from November 4, 2026. FDA says the six-month extension gives it more time to consider issues raised by interested parties. Who it hits: makers and prescribers of estrogen-androgen fixed-combination products. So what: the products face no change from that action before May 4, 2027, though the notice we read does not detail the underlying action. Confidence: High on the dates; Low on consequences. Source: Federal Register notice.